Bristol-Myers Squibb is een biofarmaceutische leider in oncologie en immunologie met een sterke track record van dividendgroei, en navigeert octrooivervallingsklffen met een robuuste overnamegerichte pipelinestrategie.
Bristol-Myers Squibb biedt een aantrekkelijk en bovengemiddeld dividendrendement voor de farmaceutische sector, ondersteund door sterke vrije kasstromgeneratie uit zijn gevestigd geneesmiddelenpakket en een toezegging om kapitaal aan aandeelhouders terug te geven.
Bristol-Myers Squibb is een toonaangevend wereldwijd farmaceutisch bedrijf met een divers portefeuille van blockbustergeneesmiddelen in oncologie, cardiologie, immunologie en fibrose, dat tientallen miljarden in jaarlijkse inkomsten genereert.
Data updated Feb 15 · Source: Twelve Data
Bristol-Myers Squibb has shown impressive recent momentum, surging nearly 35% over the past 90 days and trading near its 52-week high of $63.33. However, the 5-year return of just 1.64% highlights the longer-term challenges this large-cap pharma has faced, including patent cliffs on key drugs like Revlimid and Eliquis.
The P/E ratio of 28.65 appears elevated for a mature pharmaceutical company, though this may reflect depressed earnings from recent acquisitions and restructuring costs. BMY's dividend remains a cornerstone of the investment thesis, with a yield around 4% and a strong track record of consecutive increases befitting its Dividend Aristocrat status.
Bull case: Growing oncology and immunology pipeline (including Opdivo and recent acquisitions like Karuna Therapeutics), attractive dividend yield, and potential earnings recovery. Bear case: Significant revenue headwinds from patent expirations through 2026, heavy debt from acquisitions, and execution risk integrating new assets. BMY suits income-oriented investors willing to accept near-term uncertainty for a solid dividend and pipeline optionality.
Bristol-Myers Squibb presents a compelling value proposition within the pharmaceutical sector. Trading at a P/E ratio of roughly 11.9, the stock is priced conservatively, reflecting investor caution regarding the significant "patent cliff" facing legacy blockbusters like Revlimid and Eliquis. However, BMY is successfully executing a strategic pivot toward its new growth portfolio, including promising assets like Reblozyl and Camzyos. The stock's recent recovery from 52-week lows indicates warming market sentiment toward this turnaround story. For income-focused investors, BMY remains a standout choice due to its robust cash flow and reliable dividend history. While execution risks persist regarding pipeline delivery and debt management following recent acquisitions, the current valuation provides a reasonable margin of safety. BMY is well-suited for conservative investors seeking consistent yield and long-term capital appreciation.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Elke trader heeft een strategie die in hun hoofd geweldig eruit ziet. Backtesting is hoe je ontdekt of het werkelijk werkt. Hier is hoe je strategieën correct test, welke statistieken belangrijk zijn en waarom de meeste backtestresultaten te mooi om waar te zijn zijn.
Powered by Rexiew